Advertisement

Search Results

Advertisement



Article Topics

Your search for Andrew J. Armstrong, MD, ScM matches 3 pages

Showing 1 - 3


prostate cancer

ARCHES: Enzalutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

As reported in the Journal of Clinical Oncology by Armstrong et al, findings from the phase III ARCHES trial have shown significant improvement in radiographic progression-free survival with enzalutamide plus androgen-deprivation therapy (ADT) vs placebo plus ADT in men with metastatic...

prostate cancer

Andrew J. Armstrong, MD, ScM, on New Treatment Options in Castration-Resistant Prostate Cancer

Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castration-resistant prostate cancer and led to updates in the NCCN Guidelines for this disease.

prostate cancer

Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...

Advertisement

Advertisement



Advertisement